Fig. 6
From: HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer

HOXB2 promotes the proliferation and cisplatin resistance of OV cells via DANCR. A–B. qPCR results showing the mRNA levels of the target genes. C. Relative cell viability of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, and shHOXB2 + DANCR cell groups. Statistical significance was calculated using two-way ANOVA. D. Relative cell viability of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, shHOXB2 + DANCR cells at different concentrations of CDDP. E. Colony formation assays of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, shHOXB2 + DANCR cells treated with CDDP (10 µM for A2780/DDP, 5 µM for OV8) and equal PBS. The P-value between the two groups was calculated using an unpaired t-test. F. Apoptotic assay of siNC + Vector, siNC + DANCR, siHOXB2 + Vector, siHOXB2 + DANCR cells after treatment of CDDP (20 µM for A2780/DDP, 10 µM for OV8) and equal PBS for 24 h. The P-value between the two groups was calculated using an unpaired t-test. G. Western blotting showed the target protein level of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, shHOXB2 + DANCR cells after treatment of CDDP (20 µM for A2780/DDP, 10 µM for OV8) for 48 h. *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.0001